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Abstract: The present study evaluated the ability of five obesity-related parameters, including a
body shape index (ABSI), conicity index (CI), body roundness index (BRI), body mass index (BMI),
and waist-to-height ratio (WtHR) for predicting increased cardiometabolic risk in a population of
elderly Colombians. A cross-sectional study was conducted on 1502 participants (60.3% women,
mean age 70 ± 7.6 years) and subjects’ weight, height, waist circumference, serum lipid indices, blood
pressure, and fasting plasma glucose were measured. A cardiometabolic risk index (CMRI) was
calculated using the participants’ systolic and diastolic blood pressure, triglycerides, high-density
lipoprotein and fasting glucose levels, and waist circumference. Following the International
Diabetes Federation definition, metabolic syndrome was defined as having three or more metabolic
abnormalities. All surrogate anthropometric indices correlated significantly with CMRI (p < 0.01).
Receiver operating characteristic curve analysis of how well the anthropometric indices identified
high cardiometabolic risk showed that WtHR and BRI were the most accurate indices. The best
WtHR and BRI cut-off points in men were 0.56 (area under curve, AUC 0.77) and 4.71 (AUC 0.77),
respectively. For women, the WtHR and BRI cut-off points were 0.63 (AUC 0.77) and 6.20 (AUC 0.77),
respectively. In conclusion, BRI and WtHR have a moderate discriminating power for detecting high
cardiometabolic risk in older Colombian adults, supporting the idea that both anthropometric indices
are useful screening tools for use in the elderly.
Keywords: anthropometric indices; diagnosis criteria; metabolic syndrome; cardiometabolic
risk; elderly
1. Introduction
Metabolic syndrome (MetS) is a complex cluster of cardiovascular risk factors associated with
a sedentary lifestyle, poor nutrition, and consequent overweight. It is also strongly associated with
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other abnormalities linked to cardiovascular disease (CVD), including glucose intolerance (type 2
diabetes, impaired glucose tolerance, or impaired fasting glycemia), insulin resistance, abdominal
obesity, dyslipidemia, and hypertension [1]. Accordingly, MetS increases the risk of developing
diseases of cardiovascular origin, such as acute myocardial infarction, ischemic stroke, or coronary
heart disease [2]. Indeed, the prevalence of CVD attributable to MetS is estimated at around 12–17% [3].
Several studies have examined the presence of MetS in Latin America, reporting associated factors
including advanced age, having Hispanic or indigenous heritage, physical inactivity, high alcohol
intake, smoking, history of hypertension or type 2 diabetes (first-degree family members), and having
a low socioeconomic status (reviewed in [4]). The general prevalence of MetS in Latin-American
countries has been established as 24.9% (range: 18.8–43.3%) and is slightly more frequent in women
(25.3%) than in men (23.2%).
The clinical utility of identifying MetS in older adults has been much debated because, among the
issues raised, it has been argued that there is no consensus on the clinical criteria for screening the
elderly population to identify patients likely to be characterized with MetS. In this line, several clinical
criteria and cut-off points have been proposed. For instance, the cardiometabolic risk index (CMRI) in
older adults, measured as a continuous summary score, might represent an important intermediate or
preclinical outcome that can be measured prior to the onset of disease, and could provide opportunities
for prevention. As a marker of cardiometabolic disease risk, the use of adult CMRI severity z-scores has
been suggested as an accurate method to detect overall metabolic changes [5]. This continuous score
would be more sensitive to small and large changes that do not modify the most recent Joint Interim
Statement of the International Diabetes Federation (IDF) Task Force on Epidemiology and Prevention
criteria [6]. Thus, an increase in cholesterol from 150 to 250 mg/dl would have no impact on the IDF
score, but would be reflected as a non-trivial change in the continuous CMRI [7]. Nevertheless, there is
no validated or harmonized consensus for defining CMRI in older adults, and several continuous
CMRI scores have been reported in the literature, as described in previous narrative reviews.
Measurements of anthropometric indices are inexpensive and non-invasive, and are easily
conducted as part of normal health exams. Interestingly, anthropometric measurements such as body
mass index (BMI), waist circumference (WC), and waist-to-height ratio (WtHR) show a close correlation
with MetS components and could thus be useful surrogate markers for predicting MetS [8–10].
That being said, there remains controversy over which anthropometric indices [11] are the most
appropriate predictors of cardiometabolic disease [12]. In 2012, Krakauer and Krakauer developed
“A Body Shape Index” (ABSI), based on WC adjusted for height and weight [13], and demonstrated
that a high ABSI is associated with the accumulation of excess abdominal adipose tissue and seems
to be a substantial risk factor for premature mortality in the general population [13]. In a similar
vein, the conicity index (CI), an index of abdominal obesity, has been considered useful for detecting
central obesity, and has been studied as a predictor for alterations in fasting insulin, blood pressure,
and triglyceride levels [14]. Lastly, in 2013, Thomas and colleagues [15] developed the body roundness
index (BRI), which combines height and WC to predict the percentage of body fat. When compared with
other anthropometric indices, BRI was optimal for identifying MetS, insulin resistance, inflammatory
factors [16], and arterial stiffness [17] in obese and overweight populations. However, to date,
few studies have evaluated the predictive ability of BRI, ABSI, or CI compared with traditional metrics,
such as BMI and WtHR, with regard to CMRI in older adults [18–20].
South America has undergone a rapid epidemiologic transition, including a non-communicable
disease epidemic [21] and adverse lifestyle changes that could contribute to increase a cluster of
cardiometabolic risk factors such as MetS [4]. To the best of our knowledge, the predictive power
of anthropometric measurements, which can be measured easily in a routine health exam, has not
been assessed in elderly Latin-American individuals with high cardiovascular risk, for whom the
early detection of risk factors is essential for prevention of CVD. This is particularly true in Colombia,
where anthropometric index measurements and blood collection are not usually standard in the annual
health exam, and, to date, there have been few studies conducted in the general older population.
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For these reasons, the aim of the present study was to evaluate the prevalence of MetS using
a CMRI among older adults from Colombia, and validate the associated anthropometric surrogate
markers. We also compared the predictive ability of BRI, ABSI, CI, BMI, and WtHR to determine
whether there is a single best CMRI predictor.
2. Materials and Methods
2.1. Study Design and Participants
The data for this secondary cross-sectional study was obtained from the 2015 Colombian Health,
Well-Being and Aging Survey (SABE 2015, from the Spanish: SAlud, Bienestar and Envejecimiento,
2015), a multicenter project conducted from 2014 to 2015 by the Pan-American Health Organization and
supported by the Epidemiological Office of the Ministry of Health and Social Protection of Colombia
(https://www.minsalud.gov.co/). The survey is a cross-sectional tool for exploring and evaluating
several aspects that intervene in the phenomenon of aging and old age in the Colombian population [19].
Details of the survey have been previously published [19]. SABE 2015 was a joint venture between the
Ministry of Health and Social Protection and the Administrative Department of Science, Technology
and Innovation in Colombia.
The sample was regionally representative and involved self-representation in large cities,
with urban-rural stratification of the sample and stage selection in accordance with the municipal
map available from the Ministry of Health and Social Protection, with the following hierarchy:
municipalities, urban/rural segments, homes or sidewalks, homes, and people. The study included
the Colombian population ≥60 years old, and the indicators were disaggregated by age range, sex,
ethnicity, and socioeconomic level. To calculate the original sample size, the non-institutionalized
Colombian population aged ≥60 years was considered, and the following parameters were used:
minimum estimable proportion = 0.03, design effect = 1.2, and Relative Standard Error = 0.05 (1.2).
The universe of study comprised 99% of the population residing in private homes in both urban and
rural areas.
A total of 23,694 surveys were conducted across the country and 6365 total population segments
were investigated in 246 municipalities. As Bogotá is the capital it was independently selected,
with a total of 545 urban segments and one rural segment. The average number of adults per
segment was 4.2. The estimation of means or proportions was conducted to a level of precision
of up to 6% of the maximum expected error, at a level of national disaggregation only. The basic
procedure for the population survey was a face-to-face interview using a structured questionnaire.
The interviewers visited the selected homes, carrying the appropriate identification. At each home
visited, the standardized process involved the following: identifying the participants, registering
the demographic data, obtaining the signed informed consent, applying the established filters and
selection criteria, obtaining a signed assent form when necessary, and completion of the questionnaire
by the interviewer. A total of 1502 participants from 86 municipalities were included in this analysis.
The institutional review boards involved in developing the SABE 2015 study (the University of
Caldas, ID protocol CBCS-021-14, and the University of Valle, ID protocol 09-014 and O11-015) reviewed
and approved the study protocol. Written informed consent was obtained from each individual before
inclusion and completion of the first examination. One of the authors (C.A.C.-G.) applied to the Ministry
of Health and Social Protection of Colombia and obtained permission to use publicly available data for
research and teaching purposes (permission and details available at https://www.minsalud.gov.co/).
The study protocol for the secondary analysis was approved by the Human Subjects Committee at the
Pontificia Universidad Javeriana (ID protocol 20/2017-2017/180, FM-CIE-0459-17) in accordance with
the Declaration of Helsinki (World Medical Association) and Resolution 8430 from 1993, of the then
Colombian Ministry of Health, on technical, scientific, and administrative standards for conducting
research with humans.
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2.2. Anthropometric Measurements
The research teams of the coordinating centers (Caldas and Valle universities, Colombia)
trained the data collection staff to carry out the face-to-face interviews and physical measurements.
Anthropometric measurements included height and body weight, which were measured using a
portable stadiometer (SECA 213®, Hamburg, Germany) and an electronic scale (Kendall graduated
platform scale), respectively. BMI was estimated in kg/m2 from the measured body weight and
height. WC was measured using inextensible anthropometric tape with the subjects standing erect
and relaxed, with their arms at their sides and their feet positioned close together, parallel to the floor.
WtHR was calculated as the ratio of WC (cm) to height (cm). The other anthropometric indexes (BRI,
ABSI, and CI) were calculated using the following formulas: BRI = 364.2 − 365.5 (1 − pi-2 WC2 (m)
Height−2 (m))1/2 [15]; ABSI = WC (m)/(BMI2/3(kg/m2)Height1/2 (m)) [13]; CI = 0.109−1 WC (m) (Weight
(kg)/Height (m))−1/2 [22].
2.3. Serum Biochemical Examination
After an overnight fast, blood was collected in the morning. Blood samples were centrifuged for
10 min at 3000 rpm, 30 min after sampling. All samples were delivered to a single central laboratory
(Dinamica Laboratories, Bogotá, Colombia) for analysis within 24 h. Serum fasting glucose, low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol,
and triglycerides (TG) were analyzed using enzymatic colorimetric methods (Olympus AU5200,
Melville, NY, USA). Low-density lipoprotein cholesterol (LDL-C) was estimated using the Friedewald
equation ((LDL-C) = (Total Cholesterol) – (HDL-C) − ((TG)/5)).
2.4. Blood Pressure Determination
We measured systolic (SBP) and diastolic (DBP) blood pressure levels using an automatic blood
pressure monitor (OMRON HEM-705, Omron Healthcare Co., Ltd., Kyoto, Japan), following the
recommendations of the American College of Cardiology Foundation/American Heart Association
2011 Expert Consensus Document on Hypertension in the Elderly [23]. Values were recorded after
5 min of rest in the sitting position and three consecutive measures were obtained, waiting for at least
30 s between readings. The average of the three values for each measurement were used in the analysis.
2.5. Diagnostic Criteria of Metabolic Syndrome
MetS was defined according to the most recent Joint Interim Statement of the IDF [6] by adopting
the Ethnic Central and South American criteria for WC. Participants were classified as having MetS if
they had at least three of following metabolic risk factors or components (MetS-components): abdominal
obesity (WC ≥90 cm for Latin-American males and ≥80 cm for Latin-American females), elevated
TG (fasting serum TG ≥150 mg/dL or taking medication for abnormal lipid levels), low HDL-C
(fasting serum HDL-C <40 mg/dL in males and <50 mg/dL in females, or specific treatment for
this lipid abnormality), elevated blood pressure (SBP ≥130 mmHg or DBP ≥85 mmHg or taking
hypertension medication), or elevated fasting glucose (serum glucose level ≥100 mg/dL or taking
diabetes medication).
2.6. Definition of Cardiometabolic Risk Index
We calculated the CMRI as a continuous score of the MetS risk factors. The CMRI was calculated
using sex- and race-specific algorithms for the IDF criteria cut-off values, using the values of the
participants’ SBP and DBP, TG, HDL-C, fasting glucose, and WC. For each of these variables, a z-score
was computed as the number of standard deviation (SD) units from the sample mean after normalization
of the variables, that is, z-score = ((value − sample mean)/sample SD)). The HDL-C z-score was
multiplied by −1 to indicate higher cardiovascular risk with increasing value. Individuals with a
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CMRI ≥ 1 SD above the mean were identified as having increased cardiometabolic risk, and a lower
CMRI (<1 SD) being indicative of a healthier risk profile.
2.7. Co-Variables
For lifestyle characteristics, personal habits regarding alcohol intake (participants were categorized
as those who do not drink and those who drink less than one day per week, two to six days a week, or
every day) and cigarette smoking (participants were categorized as those who do not smoke and those
who have never-smoked, those who currently smoke or those who previously smoked) were recorded.
A “proxy physical activity” report was conducted by the following questions: (i) “Have you regularly
exercised, such as jogging or dancing, or performed rigorous physical activity at least three times a
week for the past year?”; (ii) “do you walk at least three times a week between nine and 20 blocks
(1.6 km) without resting?”; (iii) “do you walk at least three times a week eight blocks (0.5 km) without
resting?”. Participants were considered physically active if they responded affirmatively to two of the
three questions [24].
Medical information including multimorbidity, as well as chronic conditions adapted from the
original SABE study, was assessed by asking the participants if they had been medically diagnosed
with hypertension, type 2 diabetes mellitus, chronic obstructive pulmonary disease, CVD (heart attack,
angina), stroke, cancer, arthritis, osteoporosis, or sensory impairments (vision and hearing loss).
Race/ethnicity was self-reported and grouped into indigenous (people belonging to various
indigenous groups such as Ika, Kankuamo, Emberá, Misak, Nasa, Wayuu, Awuá, and Mokane); black,
“mulatto”, or Afro-Colombian; white; and other (mestizo, gypsy, etc.).
Socioeconomic status was determined on a scale of one to six based on the housing stratum,
with one representing the highest level of poverty and six the greatest wealth. This classification
was developed by the National Government of Colombia and considers the physical characteristics
of the dwellings as well as their surroundings. Classification into one of the six strata was taken to
approximate the hierarchical socioeconomic differences from poverty to wealth.
2.8. Statistical Analysis
Descriptive analyses using the mean ± SD or standard error (SE) for the continuous variables,
median and interquartile range for the skewed continuous variables, and the frequency distribution of
the categorical variables were used to determine the characteristics of the sample. Data normality was
examined using the Kolmogorov–Smirnoff test. Significant differences between men and women were
analyzed using Student’s t-test, Wilcoxon rank-sum test, or chi-square (χ2) post-hoc test. To visualize
the relationship between CMRI and anthropometric indices, Spearman and Pearson correlation and
linear regression analysis were applied to the total sample and individual genders. The linear regression
analysis was adjusted by age as a covariate.
The area under receiver operating characteristic (ROC) curves was calculated to evaluate the
abilities of the anthropometric indices to predict high CMRI. Cut-off points were proposed after
calculation of Youden’s Index (sensitivity + specificity − 1) [25]. The DeLong et al. [26] non-parametric
approach was used to compare the areas under the ROC curves. Since abdominal obesity is a component
of CMRI, we conducted a multicollinearity test for the anthropometric indices that included WC (WtHR,
CI, BRI, and ABSI), and the variance inflation factor (VIF) was calculated. Each cardiometabolic risk
factor among BMI, WtHR, BRI, ABSI, and CI was determined using analysis of variance without any
adjustment and then after adjusting (analysis of covariance, ANCOVA) for ethnicity, socio-economic
status, smoking status, alcohol intake, physical activity “proxy”, and medical conditions (i.e., presence
or absence of osteoporosis, CVD, hypertension, type 2 diabetes, cancer, or respiratory diseases) as
covariates, followed by Tukey’s test. Collinearity was tested between all anthropometric indexes that
included WC; a VFI > 10, was interpreted as high collinearity [27].
Statistical analyses were performed using SPSS v24.0 (IBM, Armonk, NY, USA) and JASP v0.9
(JASP Team, Amsterdam, The Netherlands). Statistical significance was defined as p < 0.05.
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3. Results
3.1. Baseline Characteristics of the Participants
The participants´ characteristics are summarized in Table 1. Of the 1502 older adults studied,
60.3% were women, and the mean age was 70 ± 7.6 years. The prevalence of smoking (9.7%), alcohol
intake (12.7%), and a physical activity proxy (17.7%) was relatively low, but significantly higher
in CMRI ≥ 1 SD than in CMRI < 1 SD (alcohol: 13.1% vs. 12.6%, p < 0.001). The means (SD or
range interquartile) of the WtHR, BMI, BRI, ABSI, and CI in the overall sample were 0.59 (0.1),
27.3 (24−30) kg/m2, 5.2 (4.1−6.3), 0.081 (0.078−0.085), and 22.2 (20.9−23.8), respectively. The overall
prevalence of MetS was 58.7%. Significant differences were found between the high/low CMRI status
groups for almost all characteristics, with the exception of height, LDL-C and HDL-C levels.
Table 1. Characteristics of study participants according to high (≥ 1 SD) and low (< 1 SD) cardiometabolic
risk index (CMRI) status among Colombian older adults.
Characteristics Total Sample(n = 1502)
High CMRI
≥ 1 SD (n = 397)
Low CMRI
< 1 SD (n = 1105) p-Value
Sex, n (%)
Men 596 (39.7) 141 (23.7) 455 (76.3) <0.001
Women 906 (60.3) 254 (28.0) 652 (72.0) <0.001
Socioeconomic status
1 456 (30.4) 121 (30.5) 335 (32.1) <0.001
2 635 (42.3) 176 (44.3) 459 (41.5) <0.001
3 375 (25.0) 98 (24.7) 277 (25.1) <0.001
4 29 (1.9) 2 (0.5) 27 (2.4) <0.001
>5 7 (0.5) 0 (0.0) 7 (0.6) N.A
Ethnic group
Indigenous 78 (5.2) 25 (6.3) 53 (4.8) 0.002
Black 119 (7.9) 28 (7.1) 91 (8.2) <0.001
White 396 (26.4) 106 (26.7) 290 (26.2) <0.001
Others 909 (60.5) 194 (48.9) 512 (46.3) <0.001
Smoking status, n (%)
Yes 145 (9.7) 29 (7.3) 116 (10.5) <0.001
No 1357 (90.3) 368 (92.7) 989 (89.5) <0.001
Alcohol intake, n (%)
Yes 191 (12.7) 52 (13.1) 139 (12.6) <0.001
No 1310 (87.2) 345 (86.9) 965 (87.3) <0.001
Physical Activity “proxy”, n (%)
Physically active 266 (17.7) 70 (17.6) 196 (17.7) 0.980
Non-Physically active 1231 (82.0) 323 (81.4) 908 (82.2) <0.001
Anthropometric measures/indices
Height (m) 1.55 (1.49–1.62) 1.54 (1.49–1.62) 1.55 (1.49–1.62) 0.170
Weight (kg) 64 (57–72) 71 (63–79) 62 (55–69) <0.001
Waist circumference (cm) 92 (85–100) 101 (93–107) 89 (83–97) <0.001
Body mass index (kg/m2) 27 (24–30) 29.7 (26.7–33) 26.1 (23.3–29) <0.001
WtHR 0.59 (0.1) 0.64 (0.06) 0.57 (0.06) <0.001
BRI 5.2 (4.1–6.3) 6.4 (5.3–7.7) 4.8 (3.9–5.9) <0.001
ABSI (m11/6 · kg −2/3) 0.081 (0.078–0.085) 0.083 (0.080–0.086) 0.081 (0.077–0.084) <0.001
CI 22.2 (20.9–23.8) 21.1 (19.8–22.4) 22.6 (21.4–24.1) <0.001
Metabolic syndrome components, n (%)
Prevalence of MetS 811 (58.7) 308 (77.6) 503 (45.5) <0.001
Abdominal obesity 1177 (78.4) 374 (94.2) 803 (72.7) <0.001
Hypertension 790 (52.6) 304 (76.6) 486 (44.0) <0.001
High levels of fasting glucose 465 (31.0) 220 (55.4) 245 (22.2) <0.001
High levels of triglycerides 696 (46.3) 253 (63.7) 443 (40.1) <0.001
Low levels of HDL-C 821 (54.7) 219 (55.2) 602 (54.5) 0.393
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Table 1. em Cont.
Characteristics Total Sample(n = 1502)
High CMRI
≥ 1 SD (n = 397)
Low CMRI
< 1 SD (n = 1105) p-Value
Cardiometabolic measurements
SBP (mmHg) 130 (117–145) 142 (130–163) 126 (114–140) <0.001
DBP (mmHg) 72 (65–79) 78 (72–86) 70 (64–77) <0.001
MBP (mmHg) 92 (84–101) 100 (91–111) 89 (81–97) <0.001
Total cholesterol (mg/dL) 193 (166–221) 202 (171–232) 190 (164–216) <0.001
Triglycerides (mg/dL) 144 (105–192) 174 (134–252) 134 (101–180) <0.001
LDL-C (mg/dL) 126 (102–149) 127 (103–152) 125 (102–147) 0.116
HDL-C (mg/dL) 43 (36–53) 43 (36–54) 44 (36–53) 0.740
Glucose (mg/dL) 94 (86–102) 102 (93–121) 91 (84–98) <0.001
CMRI −0.21 (−1.41–1.07) 2.00 (1.44–2.84) −0.83 (−1.83–0.05) <0.001
Self-report comorbid chronic diseases, n (%)
Hypertension 826 (55.0) 249 (62.7) 577 (52.2) <0.001
Diabetes 245 (16.3) 113 (28.5) 132 (11.9) <0.001
Respiratory diseases 165 (11.0) 49 (12.3) 116 (10.5) <0.001
Cardiovascular diseases 213 (14.2) 155 (39.0) 58 (5.2) <0.001
Stroke 70 (4.7) 22 (5.5) 48 (4.3) <0.001
Osteoporosis 184 (12.3) 66 (16.6) 118 (10.7) <0.001
Cancer 80 (5.3) 56 (14.1) 24 (2.2) <0.001
Hearing loss 360 (24.1) 89 (22.4) 271 (24.5) <0.001
Vision loss 851 (56.7) 228 (57.4) 623 (56.4) <0.001
Skewed continuous variables are reported as median and interquartile range (Q3-Q1), for non-skewed continuous
variables mean values (standard deviations (SD)) are given, and categorical variables are reported as numbers
and percentages in brackets. Significant between-sex differences (Student’s t-test, Wilcoxon rank-sum test or χ2).
BMI: body mass index; WtHR: waist-to-height ratio; BRI: body roundness index; ABSI: a body shape index; CI:
conicity index; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; CMRI:
cardiometabolic risk index. p-values marked in bold are significant.
3.2. Association between Surrogate Anthropometric Indices with CMRI
Linear regression analyses of surrogate anthropometric indices and CMRI on the total sample and
also stratified by sex are shown in Figure 1. Overall, we found an acceptable-to-moderate positive
correlation of CMRI with WtHR (r = 0.52, p < 0.001), ABSI (r = 0.17, p < 0.001), BMI (r = 0.46, p < 0.001),
and BRI (r = 0.52, p < 0.001), whereas CI was negatively correlated with CMRI (r = −0.42, p < 0.001).
When analyzing by sex, the decreasing order of the correlation coefficients in men was WtHR (r = 0.50,
p < 0.001), BRI (r = 0.50, p < 0.001), BMI (r = 0.49, p < 0.001), CI (r = −0.46, p < 0.001), and ABSI (r = 0.16,
p < 0.001), while in women the decreasing order of the correlation coefficients was WtHR (r = 0.55,
p < 0.001), BRI (r = 0.54, p < 0.001), BMI (r = 0.45, p < 0.01), CI (r = −0.44, p < 0.001), and ABSI (r = 0.22,
p < 0.001).
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Figure 1. Association between surrogate anthropometric indices and CMRI, on the total sample and
stratified by sex. BMI: body mass index; WtHR: waist to height ratio; BRI: body roundness index; ABSI:
a body shape index; CI: conicity index; CMRI: cardiometabolic risk index.
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3.3. Optimal Cut-Offs for Screening for CMRI by Sex
The ROC curve analyses of the diagnostic performance of BMI, WtHR, BRI, ABSI, and CI in
identifying a high cardiometabolic risk are shown in Table 2 and Figure 2. In men, when considering the
full sample, the best cut-off vales of BMI, WtHR, BRI, ABSI, and CI for detecting high cardiometabolic
risk (CMRI ≥ 1 SD) were 25.2 (area under curve, AUC 0.76, sensitivity 84.4% and specificity 54.7%),
0.56 (AUC 0.77, sensitivity 83.6% and specificity 58.9%), 4.71 (AUC 0.77, sensitivity 83.6% and specificity
58.9%), 0.083 (AUC 0.60, sensitivity 69.5% and specificity 53.6%), and 22.9 (AUC 0.75, sensitivity
72.3% and specificity 65.9%), respectively. For women, the best cut-off values of BMI, WtHR, BRI,
ABSI, and CI for detecting high cardiometabolic risk (CMRI ≥ 1 SD) were 28.4 (AUC 0.71, sensitivity
69.5% and specificity 64.1%), 0.63 (AUC 0.77, sensitivity 64.4% and specificity 76.7%), 6.20 (AUC 0.77,
sensitivity 65.2% and specificity 76.1%), 0.080 (AUC 0.62, sensitivity 68.7% and specificity 51.6%),
and 21.0 (AUC 0.71, sensitivity 63.6% and specificity 70.2%), respectively.
Table 2. Cut-off points, area under curve, sensitivity and specificity for BMI, WtHR, BRI, ABSI, and CI
to detect high cardiometabolic risk (CMRI ≥ 1 SD) by sex.
Parameters
BMI WtHR BRI ABSI CI
Men Women Men Women Men Women Men Women Men Women
Area under curve 0.76 0.71 0.77 0.77 0.77 0.77 0.60 0.62 0.75 0.71
p-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Optimal cut-off 25.2 28.4 0.56 0.63 4.71 6.20 0.083 0.080 22.9 21.0
Youden index J 0.39 0.33 0.42 0.41 0.42 0.41 0.23 0.20 0.38 0.33
Sensitivity (%) 84.4 69.5 83.6 64.4 83.6 65.2 69.5 68.7 72.3 63.6
Specificity (%) 54.7 64.1 58.9 76.7 58.9 76.1 53.6 51.6 65.9 70.2
(+) Likelihood ratio 1.83 1.93 2.00 2.70 2.04 2.74 1.50 1.42 2.12 2.14
(–) Likelihood ratio 0.29 0.48 0.28 0.47 0.28 0.46 0.57 0.60 0.42 0.52
BMI: body mass index; WtHR: waist to height ratio; BRI: body roundness index; ABSI: a body shape index;
CI: conicity index.
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Figure 2. Diagnostic performance of surrog te anthropometric indices to detect high risk of CMRI by
gender. BMI: body mass index; W HR: waist-to-height ratio; BRI: body roundness index; ABSI: a bo y
shape index; CI: conicity index.
The ROC curves were compared using a pairwise comparison method and the differences between
the five methods are shown in Table 3. Independently of sex, the ROC-AUC of WtHR did not
significantly differ from that of BRI. The results indicated that WtHR and BRI seem to provide the best
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results in Colombian older adults, owing to their greater precision in identifying subjects with a high
cardiometabolic risk.
Table 3. Pairwise comparison for receiver operating characteristic (ROC) curves among Colombian
older adults by sex.
Parameters BMI–WtHR
BMI–
BRI
BMI–
ABSI
BMI–
CI
WtHR–
BRI
WtHR–
ABSI
WtHR–
CI
BRI–
ABSI
BRI–
CI
ABSI–
CI
Men
Diff. AUC 0.000 0.00 0.15 0.01 0.00 0.16 0.01 0.16 0.02 0.14
SE 0.01 0.01 0.03 0.00 0.00 0.02 0.01 0.02 0.01 0.03
p-value 0.542 0.540 0.001 0.220 0.090 0.001 0.100 0.001 0.090 0.001
Women
Diff. AUC 0.06 0.06 0.08 0.00 0.00 0.15 0.06 0.15 0.06 0.08
SE 0.01 0.01 0.03 0.00 0.00 0.02 0.01 0.02 0.01 0.03
p-value 0.001 0.001 0.001 0.99 0.97 0.001 0.001 0.001 0.001 0.001
AUC: area under curve; SE: standard error; BMI: body mass index; WtHR: waist to height ratio; BRI: body roundness
index; ABSI: a body shape index; CI: conicity index. P-values marked in bold are significant.
3.4. Sex Thresholds for Surrogate Anthropometric Indices to Screen for CMRI
Thresholds were determined for each of the surrogate anthropometric indices for the low/high
CMRI in males and females, with corresponding differences in cardiometabolic parameters (Figure 2
and Table 4). In all groups (healthy/unhealthy) thresholds may be used to categorize individuals into
one of two risk categories (i.e., low and high), on the combined basis of sex and surrogate anthropometric
indices. In both sexes, after adjusting for ethnicity, socioeconomic status, smoking status, alcohol intake,
physical activity proxy, and medical conditions (presence or absence of osteoporosis, CVD, hypertension,
diabetes, cancer, and respiratory disease), the ANCOVA revealed that there were differences in blood
pressure, HDL-C, and glucose in the BMI and CI parameters. By contrast, diagnostic performance
results for CMRI without the central obesity component (i.e., WC) revealed lower accuracy (AUC) in
all thresholds for surrogate anthropometric indices (Supplementary Material Table S1).
Finally, the collinearity test for all anthropometric indices that included WC in their calculation
was found to be negative for BRI (VFI: 9.3), ABSI (VFI: 3.5), and WtHR (VFI: 9.1) and positive for CI
(VFI: 10.9).
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Table 4. Adjusted thresholds for surrogate anthropometric indices with cardiometabolic measurements among Colombian older adults by sex.
Variables Cut-Off
BMI WtHR BRI ABSI CI
Mean (SE) p-Value Mean (SE) p-Value Mean (SE) p-Value Mean (SE) p-Value Mean (SE) p-Value
Men
SBP (mmHg) healthy 130.1 (1.5) 0.001
131.7 (1.5)
0.107
131.5 (1.4)
0.045
134.7 (2.1)
0.477
131.3 (1.3)
0.005unhealthy 136.1 (1.3) 135.0 (1.3) 135.6 (1.4) 133.3 (1.1) 136.6 (1.5)
DBP (mmHg) healthy 72.3 (0.8) 0.001
73.8 (0.8)
0.250
73.7 (0.7)
0.131
76.1 (13.4)
0.176
73.1 (0.7)
0.003unhealthy 76.3 (0.7) 75.3 (0.7) 75.4 (0.7) 74.1 (0.6) 76.5 (0.8)
MBP (mmHg) healthy 91.5 (1.0) 0.001
93.1 (0.9)
0.148
92.9 (0.9)
0.064
95.5 (1.3)
0.282
92.4 (0.8)
0.003unhealthy 96.1 (0.8) 95.0 (0.8) 95.4 (0.9) 93.8 (0.7) 96.4 (0.9)
Total cholesterol (mg/dL) healthy 189.5 (2.0) 0.011
190.0 (2.5)
0.010
188.0 (2.4)
0.099
186.6 (3.5)
0.947
186.6 (2.2)
0.224unhealthy 181.8 (2.2) 181.2 (2.2) 182.4 (2.3) 184.7 (1.9) 183.1 (2.5)
Triglycerides (mg/dL) healthy 149.6 (5.7) 0.22
149.4 (5.6)
0.088
151.4 (5.3)
0.176
147.4 (7.8)
00.085
150.7 (4.9)
00.054unhealthy 162.7 (4.9) 163.2 (4.9) 162.5 (5.2) 160.0 (4.2) 165.4 (5.6)
LDL-C (mg/dL) healthy 123.5 (2.2) 0.055
123.7 (2.1)
0.058
122.5 (2.0)
0.211
119.8 (3.0)
0.511
121.3 (1.9)
0.467unhealthy 118.4 (1.8) 118.1 (1.9) 118.8 (1.9) 120.8 (1.6) 119.6 (2.1)
HDL-C (mg/dL) healthy 45.1 (0.7) 0.001
44.3 (0.7)
0.001
44.3 (12.4)
0.001
45.4 (1.0)
0.001
43.9 (0.6)
0.001unhealthy 39.5 (0.6) 39.6 (0.6) 39.3 (9.5) 40.8 (0.5) 39.2 (0.7)
Glucose (mg/dL) healthy 93.7 (1.5) 0.005
93.9 (1.5)
0.009
93.6 (1.4)
0.002
98.0 (2.1)
0.519
95.0 (1.3)
0.028unhealthy 99.1 (1.3) 99.0 (1.3) 99.8 (1.4) 96.4 (1.1) 99.0 (1.5)
CMRI
healthy −1.09 (0.1)
0.001
−1.05 (0.1)
0.001
−1.05 (0.1)
0.001
−0.66 (0.18)
0.010
−0.87 (0.11)
0.001unhealthy 0.36 (0.1) 0.36 (0.1) 0.50 (0.1) −0.13 (0.09) 0.53 (0.12)
Women
SBP (mmHg) healthy 130.4 (1.1) 0.530
130.6 (1.0)
0.942
130.6 (1.0)
0.935
129.8 (1.2)
0.639
130.4 (1.0)
0.537unhealthy 131.1 (1.1) 130.8 (1.3) 130.8 (1.3) 131.4 (1.0) 131.1 (1.2)
DBP (mmHg) healthy 70.9 (0.5) 0.021
71.6 (0.5)
0.458
71.6 (0.5)
0.414
72.0 (0.6)
0.993
71.1 (0.5)
0.034unhealthy 72.9 (10.5) 72.3 (0.6) 72.3 (0.6) 71.8 (0.5) 73.1 (0.6)
MBP (mmHg) healthy 90.6 (0.6) 0.097
91.2 (0.6)
0.721
91.2 (0.6)
0.691
91.2 (0.7)
0.823
90.8 (0.6)
0.139unhealthy 92.3 (0.7) 91.7 (0.8) 91.8 (0.8) 91.6 (0.6) 92.4 (0.7)
Total cholesterol (mg/dL) healthy 203.7 (1.9) 0.233
204.1 (1.8)
0.098
203.9 (1.8)
0.149
202.0 (2.1)
0.572
203.2 (1.8)
0.376unhealthy 200.4 (2.1) 198.8 (2.3) 199.0 (2.4) 202.2 (1.9) 200.5 (2.2)
Triglycerides (mg/dL) healthy 161.1 (4.0) 0.111
160.8 (3.7)
0.059
161.2 (3.7)
0.068
157.0 (4.4)
0.044
162.3 (3.8)
0.159unhealthy 170.8 (4.3) 173.5 (4.8) 173.4 (4.9) 172.4 (3.9) 170.7 (4.7)
LDL-C (mg/dL) healthy 132.3 (1.7) 0.258
132.6 (1.6)
0.164
132.5 (1.5)
0.132
132.0 (34.8)
0.812
132.0 (1.6)
0.381unhealthy 129.8 (1.8) 128.8 (2.0) 128.8 (2.1) 131.1 (37.4) 129.9 (2.0)
HDL-C (mg/dL) healthy 48.8 (0.6) 0.009
48.8 (0.5)
0.001
48.6 (0.5)
0.007
48.7 (13.9)
0.104
48.5 (0.5)
0.018unhealthy 46.1 (0.6) 45.4 (0.7) 45.6 (0.7) 46.9 (12.3) 46.1 (0.7)
Glucose (mg/dL) healthy 97.3 (1.1) 0.016
96.8 (1.0)
0.001
96.6 (1.0)
0.001
98.1 (1.2)
0.241
97.0 (1.0)
0.002unhealthy 101.2 (1.2) 102.9 (1.3) 103.5 (1.3) 99.9 (1.1) 102.3 (1.3)
CMRI
healthy −0.61 (0.09)
0.001
−0.57 (0.08)
0.001
−0.56 (0.08)
0.001
−0.32 (0.10)
0.001
−0.52 (0.08)
0.001unhealthy 0.82 (0.09) 1.09 (0.10) 1.16 (0.01) 0.36 (0.09) 0.94 (0.10)
Data reported as mean and standard error (SE). BMI: body mass index; WtHR: waist-to-height ratio; BRI: body roundness index; ABSI: a body shape index; CI: conicity index; SBP: systolic
blood pressure; DBP: diastolic blood pressure; MBP: mean blood pressure. p-value from ANCOVA analysis performed with ethnicity, socio-economic status, smoking status, alcohol intake,
physical activity “proxy”, and medical conditions (i.e., presence or absence of osteoporosis, cardiovascular diseases, hypertension, diabetes, cancer, or respiratory disease) as covariates.
p-values marked in bold are significant.
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4. Discussion
Metabolic abnormalities including elevated blood pressure, hypertriglyceridemia, low levels
of HDL-C, impaired glucose tolerance and central obesity, have been proposed as cardiometabolic
risk factors for CVD and all-cause mortality [28,29]. For this reason, identifying a screening tool for
detecting high cardiometabolic risk in older adults is particularly important, as this might facilitate
the early implementation of effective strategies to those at high risk. This study investigated multiple
anthropometric measurements for predicting cardiometabolic risk in a large population of older
Colombian adults. Firstly, we demonstrated that all the surrogate anthropometric indices including
BMI, WtHR, BRI, ABSI, and CI significantly correlated with CMRI. Secondly, we showed that WtHR
and BRI are the most accurate anthropometric indices for identifying adults at high cardiometabolic
risk, supporting the hypothesis that these two indices could effectively predict cardiometabolic risk in
the elderly Colombian population.
In the present study, conducted on a representative cohort of older adults, the overall prevalence
of MetS was 58.7% according to IDF criteria. These findings differ slightly from the results of
Davila et al., who showed that the prevalence of MetS among adults from Medellin (Colombia)
aged 25–64 was 41% [30]. Furthermore, the Cardiovascular Risk Factor Multiple Evaluation in Latin
America (CARMELA) study estimated a prevalence of 30.1% in men and 48.6% in women, respectively,
in the 55–64 age group in Bogotá [31]. The differences in prevalence could be explained by either the
MetS cluster used, since the CARMELA study defined MetS according to the National Cholesterol
Education Program Adult Treatment Panel III, or the age range of the target populations (55–64 vs.
≥60). Nonetheless, there is a high prevalence of MetS in Latin American populations and, accordingly,
there is growing interest in developing accurate tools for identifying subjects at high risk and defining
cut-off points for anthropometric indices for detecting high CMRI.
BRI is a novel body index that has recently shown promise for clinical use [15]. We found that
BRI has a moderate discriminating power for detecting high cardiometabolic risk in older Colombian
adults, supporting the diagnostic potential of this new shape measure. We found that BRI performed
better as a predictor of a high CMRI than BMI, the standard measure. Similarly, Tian et al. observed that
BRI was suitable for use as a single anthropometric measure for identifying a cluster of cardiometabolic
abnormalities, as compared with BMI and WtHR, using data from the 2009 wave of the China Health
and Nutrition Survey [32]. Likewise, a recent study assessing the ability of BRI to predict the risk
of MetS and its components in Peruvian adults concluded that BRI is a potentially useful clinical
predictor of MetS that performs better than BMI [18]. BRI also showed potential for use as an alternative
obesity measure in type 2 diabetes mellitus assessment among a rural population from northeastern
China, although it performed similarly to BMI [33]. Additionally, Maessen et al. found that BRI could
identify both the presence of CVD and cardiovascular risk factors in a population-based study in
Nijmegen, the Netherlands, although the authors indicated that its capacity did not exceed that of
BMI [19]. The heterogeneity of the population characteristics (ethnicity and age range) might explain
the differences between these studies.
We demonstrated that WtHR is also an accurate screening tool for detecting a high cardiometabolic
risk in older Colombian adults. Indeed, we found that WtHR was a better predictor of cardiometabolic
risk than other anthropometric indices (BMI, CI, and ABSI). Wang et al. [34] also indicated that when
evaluating cardiometabolic risk factors among non-obese adults, WtHR functioned as a simple but
effective index for Chinese adults and, similarly, Amirabdollahian et al. [35] concluded that WtHR
was the best predictor of cardiometabolic risk in a population of young adults from northwestern
England. Comparable results were reported in a previous systematic review and meta-analysis
involving 300,000 adults from several ethnic groups [36], showing the superiority of WtHR over
BMI for detecting cardiometabolic risk factors in both sexes. However, it should be noted that the
aforementioned studies did not compare WtHR with ABSI or BRI.
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Interestingly, it should be noted that the greatest AUC values were observed for WtHR and BRI in
men and women, suggesting that both body indices are capable of detecting a high cardiometabolic risk
in the elderly. In addition, the AUC of WtHR did not differ significantly from that of BRI. This highlights
the similar diagnostic capabilities of the two anthropometric indices. Furthermore, the AUC value of
BRI for identifying metabolic risk factors was very close to that of WtHR in a Chinese population of
adults [37]. In fact, Wang et al. concluded that although BRI does not exhibit a significantly better
predictive ability than WtHR, it could be used as an alternative body index [34].
Our results showed that ABSI presented the lowest AUC for high cardiometabolic risk in men
and women. These observations are consistent with previous studies [18–20,35,37,38]. Tian et al.
reported that ABSI had the weakest discriminative power for identifying a cluster of cardiometabolic
abnormalities [32]. Similarly, ABSI exhibited the lowest AUC value for identifying cardiometabolic
risk factors compared with WtHR and BRI in Chinese adults [37], and a study involving an Iranian
population also reported that ABSI was a weak predictor of CVD risk and MetS [38]. In the same line,
Stefanescu et al. found that ABSI underperformed against other measures such as BMI and BRI for
predicting MetS and its components [18], and Maessen et al. reported that ABSI was incapable of
determining the presence of CVD in a Dutch population [19]. Thus, based on both our results and
those of previous research, it can be concluded that ABSI does not seem to be a useful anthropometric
index for predicting cardiometabolic risk.
The present study has some limitations and strengths that should be mentioned. Firstly,
the cross-sectional design of the study meant that causality could not be inferred. Secondly, all of the
study participants were of Latin-American ethnicity and resident in Colombia. This may therefore
limit the generalizability of our results to other ethnic groups. Further studies involving other
populations are therefore warranted. By contrast, the main strength of our study is that we provide
gender-specific thresholds for various surrogate anthropometric indices (BMI, WtHR, BRI, ABSI,
and CI) with cardiometabolic measurements among older Colombian adults. To our knowledge,
no research has previously been published assessing the efficacy of these anthropometric indices for
predicting a high CMRI in a Latin-American population. Lastly, the large sample size and the highly
standardized procedures of the SABE project, which minimized measurement bias, were also major
strengths of this study [39,40].
5. Conclusions
In conclusion, BRI and WtHR have a moderate discriminating power for determining a high
cardiometabolic risk in a Colombian population of older adults, supporting the notion that both
anthropometric indices should be considered as screening tools for the elderly. Both anthropometric
indices were the most accurate among those tested for identifying men and women at a high
cardiometabolic risk. In addition, we provide the first BMI, WtHR, BRI, ABSI, and CI thresholds
for predicting a high CRMI in older Colombian adults. These data are clinically significant,
as anthropometric index reference thresholds can be used to identify those adults who are at high
cardiometabolic risk. Further investigation is required to provide reference values applicable to
different populations.
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